

PharmaCyte Biotech, Inc. (PMCB)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001157075

PharmaCyte Biotech, Inc.		
PMCB; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescin split-adjusted close; the letter is fixed at the rescin that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$46.8M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, late filer, thin data, degenerate inputs not computable: distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Jul 29, 2026 72 days before the rescin; latest periodic filing 10-Q received Sep 14, 2026	
Last close	\$0.40 2026-10-08; market equity \$4.3M	
Price used in grade	None	

Letter at every rescin

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A
B
C
D
E

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Business, in the company's words

opening of Item 1 of the 10-K received Jul 29, 2026

cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as "CypCaps?." Scientific Committee (the "Scientific Committee"), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte. Ltd.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 15.3						

Gross profitability		not computable	32.2%			latest aligned inputs end 2016-04-30; latest annual assets end 2026-04-30
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(28.0%)	(6.6%)	15.3	811	2026-04-30
Gross margin stability, five years		not computable	2.8 pts			annual revenue must exceed \$100,000
Solvency, sleeve percentile 18.9						
Twelve-month failure probability		not computable	0.07%			four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime		(0.16)	(0.31)	37.4	756	2026-04-30
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		45.28x	2.96x	0.4	839	2026-04-30
Growth and financing, sleeve percentile 76.4						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(13.9%)	2.1%	74.4	704	2026-04-30
Net share issuance, one year		58.0%	2.5%	78.4	634	2026-07-24

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 58.0%

Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(48.3%)	8.0%	15
Distance from 52-week high	(67.4%)	(31.4%)	13
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	6.45	0.28	100
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.87)	(0.14)	15

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-04-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$17.7M
Operating cash flow, four quarters	-\$3.9M
Months of runway	54.0
Days since last periodic filing	25 (10-Q received Sep 14, 2026)
Median daily dollar volume, 63 sessions	\$53,228

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$0	2016-04-30	2016-07-29	10-K	0001019687-16-007057
2	assets	us-gaap:Assets	\$7.2M	2016-04-30	2017-07-27	10-K	0001683168-17-001881
3	net income	us-gaap:NetIncomeLoss	-\$19.4M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$5.2M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
5	assets	us-gaap:Assets	\$46.8M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
6	assets	us-gaap:Assets	\$55.2M	2025-04-30	2026-07-29	10-K	0001683168-26-005836
7	revenue	us-gaap:Revenues	\$0	2016-04-30	2017-07-27	10-K	0001683168-17-001881
8	current assets	us-gaap:AssetsCurrent	\$37.4M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
9	current liabilities	us-gaap:LiabilitiesCurrent	\$826,424	2026-04-30	2026-07-29	10-K	0001683168-26-005836
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$104.4M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
11	operating income	us-gaap:OperatingIncomeLoss	-\$6.9M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
12	book equity	us-gaap:StockholdersEquity	\$33.3M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
13	liabilities	us-gaap:Liabilities	\$11.8M	2026-04-30	2026-07-29	10-K	0001683168-26-005836
14	operating income	us-gaap:OperatingIncomeLoss	-\$6.5M	2023-04-30	2024-08-13	10-K	0001683168-24-005575
15	interest expense	us-gaap:InterestExpense	\$0	2023-04-30	2023-07-31	10-K	0001683168-23-005175
16	revenue	us-gaap:Revenues	\$0	2026-04-30	2026-07-29	10-K	0001683168-26-005836
17	revenue	us-gaap:Revenues	\$0	2025-04-30	2026-07-29	10-K	0001683168-26-005836
18	revenue	us-gaap:Revenues	\$0	2024-04-30	2025-08-11	10-K	0001683168-25-005821
19	revenue	us-gaap:Revenues	\$0	2023-04-30	2024-08-13	10-K	0001683168-24-005575

20	assets	us-gaap:Assets	\$59.9M	2024-04-30	2025-08-11	10-K	0001683168-25-005821
21	assets	us-gaap:Assets	\$73.3M	2023-04-30	2024-08-13	10-K	0001683168-24-005575
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,735,649	2026-07-24	2026-07-29	10-K	0001683168-26-005836
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,795,779	2025-08-04	2025-08-11	10-K	0001683168-25-005821